Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E
Blood Adv
.
2022 Aug 23;6(16):4901-4904.
doi: 10.1182/bloodadvances.2022007519.
Authors
Paul Milne
1
,
Harshal Abhyankar
2
,
Brooks Scull
2
,
Preeti Singh
1
,
Rikhia Chakraborty
2
,
Carl E Allen
2
3
,
Matthew Collin
1
Affiliations
1
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; and.
2
Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX; and.
3
Baylor College of Medicine, Houston, TX.
PMID:
35816634
PMCID:
PMC9631653
DOI:
10.1182/bloodadvances.2022007519
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
MeSH terms
Disease Susceptibility
Histiocytosis, Langerhans-Cell* / genetics
Humans
Mutation
Grants and funding
21025/CRUK_/Cancer Research UK/United Kingdom
P50 CA126752/CA/NCI NIH HHS/United States
R01 CA154489/CA/NCI NIH HHS/United States
R01 CA154947/CA/NCI NIH HHS/United States